LU90468I2 - Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable - Google Patents

Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable

Info

Publication number
LU90468I2
LU90468I2 LU90468C LU90468C LU90468I2 LU 90468 I2 LU90468 I2 LU 90468I2 LU 90468 C LU90468 C LU 90468C LU 90468 C LU90468 C LU 90468C LU 90468 I2 LU90468 I2 LU 90468I2
Authority
LU
Luxembourg
Prior art keywords
zanamivir
derivative
optionally
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
LU90468C
Other languages
English (en)
Original Assignee
Biota Scient Management
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biota Scient Management filed Critical Biota Scient Management
Publication of LU90468I2 publication Critical patent/LU90468I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU90468C 1990-04-24 1999-11-03 Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable LU90468I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPJ980090 1990-04-24
AUPK289690 1990-10-19
AUPK453791 1991-02-11
PCT/AU1991/000161 WO1991016320A1 (fr) 1990-04-24 1991-04-24 Derives et analogues d'acide 2-deoxy-2,3-didehydro-n-acetyle neuraminique et leur utilisation comme agents antiviraux

Publications (1)

Publication Number Publication Date
LU90468I2 true LU90468I2 (fr) 2000-01-03

Family

ID=27157556

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90468C LU90468I2 (fr) 1990-04-24 1999-11-03 Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable

Country Status (37)

Country Link
US (2) US5360817A (fr)
EP (2) EP0786458B1 (fr)
JP (1) JP2944750B2 (fr)
KR (1) KR0169496B1 (fr)
CN (3) CN1143853C (fr)
AP (1) AP249A (fr)
AT (2) ATE161253T1 (fr)
AU (2) AU7533891A (fr)
BG (1) BG62092B1 (fr)
CA (2) CA2081356C (fr)
CY (1) CY2186B1 (fr)
CZ (1) CZ288492B6 (fr)
DE (3) DE69133604D1 (fr)
DK (1) DK0526543T3 (fr)
ES (2) ES2113881T3 (fr)
FI (2) FI105478B (fr)
GR (1) GR3026225T3 (fr)
HK (1) HK1003834A1 (fr)
HU (2) HU219355B (fr)
IE (2) IE911372A1 (fr)
IL (1) IL97936A (fr)
LU (1) LU90468I2 (fr)
MY (1) MY107843A (fr)
NL (1) NL990030I2 (fr)
NO (3) NO302751B1 (fr)
NZ (1) NZ237936A (fr)
OA (1) OA09679A (fr)
PL (3) PL167192B1 (fr)
PT (1) PT97460B (fr)
RU (1) RU2119487C1 (fr)
SG (1) SG43170A1 (fr)
SI (1) SI9110745B (fr)
SK (1) SK282950B6 (fr)
UA (1) UA41252C2 (fr)
WO (1) WO1991016320A1 (fr)
YU (1) YU48741B (fr)
ZA (1) ZA913086B (fr)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU659501B2 (en) * 1991-10-23 1995-05-18 Biota Scientific Management Pty Ltd Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-D-neuraminic acid
GB9126725D0 (en) * 1991-12-17 1992-02-12 Glaxo Group Ltd Process
GB9220241D0 (en) * 1992-09-25 1992-11-11 Glaxo Group Ltd Process
GB9220327D0 (en) * 1992-09-25 1992-11-11 Glaxo Group Ltd Process
GB9312531D0 (en) * 1993-06-17 1993-08-04 Glaxo Group Ltd Process
US5958973A (en) * 1993-09-03 1999-09-28 Gilead Sciences, Inc. Polyhydroxy benzoic acid derivatives and their use as neuraminidase inhibitors
GB9325841D0 (en) 1993-12-17 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9400206D0 (en) * 1994-01-07 1994-03-02 Glaxo Group Ltd Chemical compound
AUPM354694A0 (en) * 1994-01-27 1994-02-17 Biota Scientific Management Pty Ltd Chemical compounds
US5985859A (en) * 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
US5453533A (en) * 1994-04-14 1995-09-26 The University Of Alabama At Birmingham Inhibitors of influenza virus neuraminidase and methods of making and using the same
DE69515101T2 (de) * 1994-05-27 2000-07-13 Daikin Industries, Ltd. 7-fluoro-2,3-didehydrosialinsäure und zwischenprodukte in ihrer synthese
GB9410817D0 (en) * 1994-05-28 1994-07-20 Glaxo Group Ltd Medicaments
AUPM725794A0 (en) * 1994-08-03 1994-08-25 Biota Scientific Management Pty Ltd Chemical compounds
US5556963A (en) * 1994-08-05 1996-09-17 Oklahoma Medical Research Foundation Synthesis of 4-alkoxy-N-acetylneuraminic acid
GB9416365D0 (en) * 1994-08-12 1994-10-05 Glaxo Group Ltd Medicaments
US5512596A (en) * 1994-09-02 1996-04-30 Gilead Sciences, Inc. Aromatic compounds
US5475109A (en) * 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
AU4259500A (en) * 1995-02-27 2000-08-31 Gilead Sciences, Inc. Novel compounds and methods for synthesis and therapy
US5866601A (en) * 1995-02-27 1999-02-02 Gilead Sciences, Inc. Carbocyclic compounds
CN103772231B (zh) * 1995-02-27 2016-02-03 吉里德科学公司 新颖化合物，其合成方法及治疗用途
CN101143859A (zh) * 1995-02-27 2008-03-19 吉里德科学公司 新颖化合物,其合成方法及治疗用途
CN100409844C (zh) 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
US5602277A (en) * 1995-03-30 1997-02-11 Biocryst Pharmaceuticals, Inc. Substituted benzene derivatives useful as neuraminidase inhibitors
US5714509A (en) * 1995-05-03 1998-02-03 The University Of Alabama Inhibitors of bacterial sialidase and methods of making and using the same
HUP9801766A3 (en) * 1995-05-19 2000-09-28 Biota Scient Managemant Pty Lt 6-carboxamido dihydropyran derivatives, process for producing them and medicaments containing the same
GB9516276D0 (en) * 1995-08-08 1995-10-11 Biota Scient Management Chemical compounds
JPH0967270A (ja) * 1995-08-31 1997-03-11 Res Dev Corp Of Japan 水晶体混濁の予防および治療法、並びにそのための薬 剤
US5763483A (en) * 1995-12-29 1998-06-09 Gilead Sciences, Inc. Carbocyclic compounds
HU223099B1 (hu) * 1996-03-01 2004-03-29 Biota Scientific Managemant Pty. Ltd. Eljárás influenzavírus kimutatására és az eljárásban alkalmazható vegyületek
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US6451766B1 (en) 1996-07-22 2002-09-17 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
US6340702B1 (en) 1996-07-22 2002-01-22 Sankyo Company, Limited Neuraminic acid derivatives, their preparation and their medical use
DE69709795T2 (de) * 1996-07-22 2002-09-26 Sankyo Co., Ltd. Neuraminsäuredervate, ihre Herstellung und medizinische Verwendung
HU226130B1 (en) * 1996-08-13 2008-05-28 Daiichi Sankyo Company Neuraminic acid compounds, medicaments containing the same and method for producing the same medicaments
US6518438B2 (en) 1996-08-23 2003-02-11 Gilead Sciences, Inc. Preparation of cyclohexene carboxylate derivatives
US5859284A (en) * 1996-08-23 1999-01-12 Gilead Sciences, Inc. Preparation of carbocyclic compounds
EP0882721A4 (fr) * 1996-09-10 1999-12-22 Daikin Ind Ltd Acides sialiques 2,7-dideoxy-7-fluoro- 2, 3-didehydro a quadruple substitution
US5719020A (en) * 1996-09-25 1998-02-17 Oklahoma Medical Research Foundation 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinical specimens
WO1998017647A1 (fr) * 1996-10-21 1998-04-30 Gilead Sciences, Inc. Composes de piperidine
US5994377A (en) * 1996-10-21 1999-11-30 Gilead Sciences, Inc. Piperidine compounds
AU732916C (en) 1996-11-14 2002-06-06 Biota Scientific Management Pty Ltd Method and novel compounds for use therein
US5886213A (en) * 1997-08-22 1999-03-23 Gilead Sciences, Inc. Preparation of carbocyclic compounds
JP3390965B2 (ja) 1997-09-12 2003-03-31 理化学研究所 糖結合スフィンゴシンを含有するポリマー化合物
US20040053999A1 (en) * 1997-09-17 2004-03-18 Bischofberger Norbert W. Novel compounds and methods for synthesis and therapy
JP2001516739A (ja) * 1997-09-17 2001-10-02 ギリアード サイエンシーズ， インコーポレイテッド ６員環を含む化合物、それらの調製プロセス、および医薬としてのそれらの使用
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
TW477783B (en) * 1997-12-12 2002-03-01 Gilead Sciences Inc Novel compounds useful as neuraminidase inhibitors and pharmaceutical compositions containing same
JP2002521312A (ja) * 1998-04-23 2002-07-16 アボット・ラボラトリーズ ノイラミニダーゼの阻害剤
US6455571B1 (en) 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
US6518305B1 (en) 1998-04-23 2003-02-11 Abbott Laboratories Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases
BR9912062A (pt) 1998-07-15 2001-04-03 Hassan Jomaa Compostos orgânicos fosforosos e seu uso
US6303764B1 (en) 1998-09-24 2001-10-16 Zymetx, Inc. Synthesis of 4,7-dialkyl chromogenic glycosides of N-acetylneuraminic acids
US6664235B1 (en) 1999-08-20 2003-12-16 Riken Medicaments comprising sialic acid derivatives as active ingredients
US6420552B1 (en) 1999-09-10 2002-07-16 Zymetx, Inc. Syntheses of 4-alkyl chromogenic glycosides and 7-alkyl chromogenic glycosides of N-acetylneuraminic acids
AU2039301A (en) * 1999-10-19 2001-04-30 Abbott Laboratories Neuraminidase inhibitors
US6593314B1 (en) 1999-10-19 2003-07-15 Abbott Laboratories Neuraminidase inhibitors
US6627396B1 (en) 1999-10-28 2003-09-30 The Regents Of The University Of California Influenza sensor
SE9904289D0 (sv) * 1999-11-26 1999-11-26 Niklas Arnberg Method and camposition for the treatment of adenovairal ocular infections
NZ521255A (en) 2000-03-06 2007-01-26 Univ Kentucky Res Found Methods to impair hematologic cancer progenitor cells and compounds related thereto
GB0015324D0 (en) * 2000-06-22 2000-08-16 Biota Scient Management Medicaments
AUPR001000A0 (en) 2000-09-08 2000-10-05 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
EP1438387A4 (fr) * 2001-09-14 2004-10-13 Momenta Pharmaceuticals Inc Procedes de fabrication de glycomolecules a activite amelioree, et utilisations de ces dernieres
JP2006241024A (ja) * 2005-03-01 2006-09-14 Takashi Suzuki 新規シアル酸誘導体
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
CN100471848C (zh) * 2006-06-05 2009-03-25 中国医学科学院医药生物技术研究所 一组长链烷氧烷基取代唾液酸衍生物及其制备方法
US20080063722A1 (en) * 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
WO2008090151A1 (fr) 2007-01-23 2008-07-31 Therapicon Srl Composés antiviraux
US20080194801A1 (en) * 2007-02-14 2008-08-14 Swanson Basil I Robust multidentate ligands for diagnosis and anti-viral drugs for influenza and related viruses
US7981930B2 (en) * 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP2010524467A (ja) 2007-04-16 2010-07-22 モメンタ ファーマシューティカルズ インコーポレイテッド 規定の糖タンパク質産物および関連の方法
EP2190439B1 (fr) * 2007-08-31 2016-03-09 Academia Sinica Dérivés phosphonate de l'oseltemivir ayant une activité anti-grippale et leur synthèse
EP2276479B1 (fr) 2008-04-15 2014-07-02 SineVir Therapeutics LLC Promédicaments d'inhibiteurs de la neuraminidase
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
JP2012510456A (ja) 2008-11-28 2012-05-10 シプラ・リミテッド ザナミビルの製造方法及び該方法に使用するための中間体
TWI491416B (zh) 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
EP2228054A1 (fr) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Suspensions aqueuses au riluzole
WO2010127443A1 (fr) * 2009-05-04 2010-11-11 National Research Council Of Canada Inhibiteurs de la sialidase ou d'enzymes analogues à la sialidase
NZ610978A (en) * 2009-05-15 2014-11-28 Redx Pharma Ltd Redox drug derivatives
CA2767453C (fr) * 2009-07-15 2018-10-09 The University Of British Columbia Composes inhibiteurs de neuraminidase, compositions et methodes d'utilisation associees comme antiviraux
CN102612514B (zh) * 2009-07-16 2016-01-13 格里菲斯大学 抗流感剂
IT1396620B1 (it) 2009-11-25 2012-12-14 Therapicon Srl Analoghi chimerici
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
JP2011136964A (ja) * 2009-12-28 2011-07-14 Gifu Univ ノイラミン酸誘導体、シアリダーゼ活性阻害剤及び抗インフルエンザ薬
WO2011127322A1 (fr) 2010-04-07 2011-10-13 Momenta Pharmaceuticals, Inc. Glycanes à haute teneur en mannose
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
AU2011250970B2 (en) 2010-05-10 2016-12-15 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
CN101921251B (zh) * 2010-09-21 2011-10-05 仙居县圃瑞药业有限公司 扎那米韦中间体的精制工艺方法
CN102464640A (zh) * 2010-10-29 2012-05-23 江苏正大天晴药业股份有限公司 扎那米韦的制备方法
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
WO2012114350A1 (fr) 2011-02-24 2012-08-30 Cadila Healthcare Limited Procédé de préparation de zanamivir
EP2686671A4 (fr) 2011-03-12 2015-06-24 Momenta Pharmaceuticals Inc N-glycanes contenant de la n-acétylhexosamine dans des produits de glycoprotéines
WO2012142492A2 (fr) * 2011-04-15 2012-10-18 University Of Georgia Research Foundation, Inc. Procédés permettant d'inhiber la réplication de virus
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
WO2013093458A2 (fr) 2011-12-21 2013-06-27 Redx Pharma Limited Dérivés de médicament antiviraux
KR102128413B1 (ko) * 2012-01-19 2020-07-01 더 유니버시티 오브 브리티쉬 콜롬비아 3' 적도방향 불소 치환된 뉴라미니다제 저해제 화합물 및 항바이러스제로 사용하기 위한 이의 조성물 및 방법
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013181575A2 (fr) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Méthodes associées au denosumab
EP2877589B1 (fr) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoprotéines ayant des propriétés anti-inflammatoires
WO2014031498A1 (fr) 2012-08-18 2014-02-27 Academia Sinica Sondes perméables aux cellules pour l'identification et l'imagerie de sialidases
EP2912047B1 (fr) 2012-10-29 2016-08-24 Cipla Limited Analogues de phosphonate antiviraux et leur procédé de préparation
US10450361B2 (en) 2013-03-15 2019-10-22 Momenta Pharmaceuticals, Inc. Methods related to CTLA4-Fc fusion proteins
WO2014186310A1 (fr) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Méthodes de traitement de la neurodégénérescence
EP3013365B1 (fr) 2013-06-26 2019-06-05 Academia Sinica Antigènes rm2 et leur utilisation
EP3013347B1 (fr) 2013-06-27 2019-12-11 Academia Sinica Conjugués de glycane et leur utilisation
CN103396957B (zh) * 2013-07-11 2015-08-19 中国海洋大学 一种来源于鲤链霉菌的海洋微生物多糖及其制备方法
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
WO2015032357A1 (fr) * 2013-09-09 2015-03-12 中国科学院上海有机化学研究所 Zanamivir, intermédiaire du zanamivir et procédé de synthèse
WO2015057622A1 (fr) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Glycoprotéines sialylées
JP6453050B2 (ja) * 2013-11-15 2019-01-16 国立大学法人富山大学 ２−デオキシ−２，３−ジデヒドロシアル酸誘導体およびその製造法
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
US20170100385A1 (en) 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
CA2950415A1 (fr) 2014-05-27 2015-12-03 Academia Sinica Glycoanticorps anti-cd20 et leurs utilisations
WO2015184001A1 (fr) 2014-05-28 2015-12-03 Academia Sinica Glycoanticorps anti-thf-alpha et leurs utilisations
NL2013420B1 (en) * 2014-09-05 2016-09-27 Univ Griffith Antiviral agents and uses thereof.
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
JP6647207B2 (ja) 2014-10-24 2020-02-14 ペプチドリーム株式会社 ヘマグルチニン結合ペプチド
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
EP3426693A4 (fr) 2016-03-08 2019-11-13 Academia Sinica Procédés de synthèse modulaire de n-glycanes et de puces à n-glycanes
CA3034057A1 (fr) 2016-08-22 2018-03-01 CHO Pharma Inc. Anticorps, fragments de liaison, et procedes d'utilisation
CN106520864A (zh) * 2016-09-28 2017-03-22 南京农业大学 一种酶法合成唾液酸类似物的方法及其应用
WO2018213933A1 (fr) * 2017-05-25 2018-11-29 The Governors Of The University Of Alberta Méthodes de prévention ou de traitement de l'athérosclérose avec des inhibiteurs d'isoenzymes spécifiques de la neuraminidase humaine
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation
EP4452220A1 (fr) 2021-12-23 2024-10-30 Subintro Limited Nouvelles compositions antivirales comprenant de l'acide oléique
US20230310474A1 (en) * 2022-02-11 2023-10-05 Cleveland State University Coronavirus treatment composition and method

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL287642A (fr) 1962-01-18

Also Published As

Publication number Publication date
NO302751B1 (no) 1998-04-20
WO1991016320A1 (fr) 1991-10-31
CN1143853C (zh) 2004-03-31
NL990030I2 (nl) 2000-02-01
UA41252C2 (uk) 2001-09-17
CN1057260A (zh) 1991-12-25
FI20001231L (fi) 2000-05-23
SI9110745B (en) 2001-06-30
KR0169496B1 (ko) 1999-01-15
BG62092B1 (bg) 1999-02-26
EP0786458A2 (fr) 1997-07-30
CA2081356A1 (fr) 1991-10-25
ATE406358T1 (de) 2008-09-15
FI20001231A7 (fi) 2000-05-23
AP9100253A0 (en) 1991-04-30
IE980526A1 (en) 2003-10-15
CA2291994A1 (fr) 1991-10-25
AP249A (en) 1993-03-17
HUT61989A (en) 1993-03-29
NO974670D0 (no) 1997-10-09
NO923944L (no) 1992-12-18
EP0526543B1 (fr) 1997-12-17
HU9203180D0 (en) 1992-12-28
JPH05507068A (ja) 1993-10-14
MY107843A (en) 1996-06-29
SK282950B6 (sk) 2003-01-09
CN1036849C (zh) 1997-12-31
CZ288492B6 (en) 2001-06-13
DE69128469D1 (de) 1998-01-29
US5648379A (en) 1997-07-15
CS114591A3 (en) 1991-12-17
SG43170A1 (en) 1997-10-17
PL167192B1 (pl) 1995-08-31
NL990030I1 (nl) 1999-12-01
JP2944750B2 (ja) 1999-09-06
HU219355B (en) 2001-03-28
CN1184108A (zh) 1998-06-10
HU210717A9 (en) 1995-06-28
NO974670L (no) 1992-12-18
CA2081356C (fr) 2000-02-22
EP0526543A1 (fr) 1993-02-10
IE911372A1 (en) 1991-11-06
ES2313730T3 (es) 2009-03-01
FI105478B (fi) 2000-08-31
DE19975068I2 (de) 2002-10-10
RU2119487C1 (ru) 1998-09-27
OA09679A (en) 1993-05-15
BG96978A (bg) 1993-12-24
PL166918B1 (pl) 1995-07-31
AU7533891A (en) 1991-12-12
FI924790A0 (fi) 1992-10-22
DE19975068I1 (de) 2000-01-13
PL167630B1 (pl) 1995-10-31
IL97936A (en) 1995-12-08
EP0786458A3 (fr) 1999-10-13
AU7759091A (en) 1991-11-11
CN1150020A (zh) 1997-05-21
FI924790L (fi) 1992-10-22
GR3026225T3 (en) 1998-05-29
YU74591A (sh) 1994-06-24
ATE161253T1 (de) 1998-01-15
PT97460B (pt) 1999-01-29
US5360817A (en) 1994-11-01
DE69128469T2 (de) 1998-06-04
CA2291994C (fr) 2003-10-14
ZA913086B (en) 1992-12-30
NZ237936A (en) 1997-08-22
NO923944D0 (no) 1992-10-09
EP0786458B1 (fr) 2008-08-27
HK1010191A1 (en) 1999-06-17
HK1003834A1 (en) 1998-11-06
DE69133604D1 (de) 2008-10-09
CY2186B1 (en) 2002-11-08
ES2113881T3 (es) 1998-05-16
PT97460A (pt) 1992-01-31
NO1999021I1 (no) 1999-09-17
YU48741B (sh) 1999-09-27
AU654815B2 (en) 1994-11-24
CN1091594C (zh) 2002-10-02
EP0526543A4 (en) 1993-04-21
SI9110745A (en) 1997-04-30
DK0526543T3 (da) 1998-08-24

Similar Documents

Publication Publication Date Title
LU90468I2 (fr) Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU88809I2 (fr) Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable
LU90593I2 (fr) Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe
LU90426I2 (fr) Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU91290I2 (fr) Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)
LU92407I2 (fr) Afatinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable, y compris le sel dimaléate
LU92428I2 (fr) Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
LU91372I2 (fr) Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
LU91027I2 (fr) Dutasteride optionnellement sous forme d'un solvate pharmaceutiquement acceptable
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
LU91442I2 (fr) "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU88746I2 (fr) Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique
LU92699I2 (fr) Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués
YU58190A (en) Aminoacid's derivatives
MA21682A1 (fr) Procede de preparation d'agents therapeutiques derives de la quainclidine.
EP0701874A3 (fr) Machine à coulée sous pression
CA2091343A1 (fr) Methode de preparation de formoterol et de composes apparentes
FR2646925B1 (fr) Sonar d'evitement d'objets sous-marins sub-surface
ITMI911272A0 (it) Macchina per la sostituzione delle traversine
ITMI920045A1 (it) Macchina posabinario per l'abbassamento controllato di un binario
FI901239A7 (fi) Menetelmä farmaseuttisesti aktiivisen 1,3,4,6,7,8-heksahydro-2H-pyrimido-(1,2-a)-pyrimidiinijohdannaisen valmistamiseksi
FI930411A7 (fi) Bombesin antagonister
FR2607676B1 (fr) Procede d'obtention de compositions alimentaires sous forme de mousse
LU90070I2 (fr) Zafirlukast optionnellement sous forme d'un sel de celui-ci